International Journal of Drug Policy
Volume 14, Issue 5 , Pages 425-430 , December 2003

Injecting behaviour of injecting drug users at needle and syringe programmes and pharmacies in Australia

  • Hla-Hla Thein

      Affiliations

    • National Centre in HIV Epidemiology and Clinical Research Level 2, 376 Victoria Street, Darlinghurst, NSW 2010, Australia
    • Corresponding Author InformationCorresponding author. Fax: +61-2-9332-1837.
    • ,
  • Marl Denoe

      Affiliations

    • Kirketon Road Centre, P.O. Box 22, Kings Cross, NSW 1340, Australia
    • Fax: +61-2-9360-5154.
    • ,
  • Ingrid van Beek

      Affiliations

    • Kirketon Road Centre, P.O. Box 22, Kings Cross, NSW 1340, Australia
    • Fax: +61-2-9360-5154.
    • ,
  • Gregory Dore

      Affiliations

    • National Centre in HIV Epidemiology and Clinical Research Level 2, 376 Victoria Street, Darlinghurst, NSW 2010, Australia
    • ,
  • Margaret MacDonald

      Affiliations

    • National Centre in HIV Epidemiology and Clinical Research Level 2, 376 Victoria Street, Darlinghurst, NSW 2010, Australia

Received 1 December 2002 ,Revised 15 March 2003 ,Accepted 24 June 2003.

References 

  1. Bluthenthal RN, Kral AH, Erringer EA, Edlin BR. Use of an illegal syringe exchange and injection-related risk behaviours among street-recruited injection drug users in Oakland, CA, 1992–1995. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 1998;18(5):505–511
  2. Commonwealth of Australia. (2002). Return on Investment in Needle and Syringe Programmes in Australia. Report. Canberra: Department of Health and Ageing.
  3. Cotten-Oldenburg NU, Carr P, DeBoer JM, Collison EK, Novotny G. Impact of pharmacy-based syringe access on injection practices among injecting drug users in Minnesota 1998–1999. Journal of Acquired Immune Deficiency Syndromes. 2001;27(2):183–192
  4. De Irala J, Bigelow C, McCusker J, Hindin R, Zheng L. Reliability of self-reported human immunodeficiency virus risk behaviours in a residential drug treatment population. American Journal of Epidemiology. 1996;143(7):725–732
  5. Des Jarlais DC, McKnight C, Friedmann P. Legal syringe purchases by injection drug users, Brooklyn and Queens, New York City, 2000–2001. Journal of the American Pharmaceutical Association. 2002;42(6 Suppl. 2):S73–S76
  6. Des Jarlais DC, Paone D, Milliken J, Turner CF, Miller H, et al.  Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: A quasi-randomised trial. Lancet. 1999;353(9165):1657–1661 (comment)
  7. Hagan H, Jarlais DC, Friedman SR, Purchase D, Alter MJ. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. American Journal of Public Health. 1995;85(11):1531–1537 (comment)
  8. Hahn JA, Vranizan KM, Moss AR. Who uses needle exchange? A study of injection drug users in treatment in San Francisco 1989–1990. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 1997;15(2):157–164
  9. Hutchinson SJ, Taylor A, Goldberg DJ, Gruer L. Addiction. 2000;95(6):931–940
  10. Lenton S, Kerry K, Loxley W, Tan-Quigley A, Greig R. Citizens who inject drugs: The ‘Fitpack’ study. International Journal of Drug Policy. 2000;11:285–297
  11. Longshore D, Bluthenthal RN, Stein MD. Needle exchange program attendance and injection risk in Providence, Rhode Island. AIDS Education and Prevention. 2001;13(1):78–90
  12. MacDonald M, Wodak AD, Ali R, Crofts N, Cunningham PH, et al.  HIV prevalence and risk behaviour in needle exchange attenders: A national study. The Collaboration of Australian Needle Exchanges. Medical Journal of Australia. 1997;166(5):237–240
  13. Miller CL, Tyndall M, Spittal P, Li K, Palepu A, et al.  Risk-taking behaviours among injecting drug users who obtain syringes from pharmacies fixed sites and mobile van needle exchanges. Journal of Urban Health. 2002;79(2):257–265
  14. National Centre in HIV Epidemiology and Clinical Research. (2002). Annual Surveillance Report. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. Sydney: NCHECR, The University of NSW.
  15. Reich W, Compton WM, Horton JC, Cottler LB, Cunningham-Williams RM, et al.  Injection drug users report good access to pharmacy sale of syringes. Journal of the American Pharmaceutical Association. 2002;42(6 Suppl. 2):S68–S72
  16. Richard AJ, Mosier V, Atkinson JS. New syringe acquisition and multi-person use of syringes among illegal drug users. Journal of Public Health Policy. 2002;23(3):324–343
  17. Shapshak P, McCoy CB, Shah SM, Page JB, Rivers JE, et al.  Preliminary laboratory studies of inactivation of HIV-1 in needles and syringes containing infected blood using undiluted household bleach. Journal of Acquired Immune Deficiency Syndromes. 1994;7(7):754–759 (comment)
  18. Strathdee SA, Patrick DM, Currie SL, et al.  Needle exchange is not enough: Lessons from the Vancouver injecting drug use study. AIDS. 1997;11(8):F59–F65
  19. Topp, L., Kaye, S., Bruno, R., Longo, M. (2002). Australian Drug Trends 2001. Findings of the Illicit Drug Reporting System (IDRS). National Drug and Alcohol Research Centre Monograph Number 48. Sydney.
  20. Tortu S, Deren S, Beardsley M, Hamid R. Factors associated with needle exchange use in East Harlem, New York City. Journal of Drug Issues. 1996;26(4):735–749
  21. Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. The Journal of the American Medical Association. 1994;271(2):115–120

PII: S0955-3959(03)00150-6

doi: 10.1016/j.drugpo.2003.06.001

International Journal of Drug Policy
Volume 14, Issue 5 , Pages 425-430 , December 2003

Article Tools